TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: caloric intake of children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 10-year cause-specific survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of nursing caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Angle of tilt and decentration of IOL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total biopsy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of aspirations per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum glucose infusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean times for maximal metabolic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Onset of action
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: abortion rates within 12 h
Endpoint domain: Mortality/survival
Primary endpoint: abortion rates within 24 h
Endpoint domain: Mortality/survival
Primary endpoint: induction-abortion intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time interval to the first compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of teams giving the first defibrillatory shock within 5 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ad libitum absolute energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic floor muscle function (mean contractions)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: magnitude, breadth and durability of cellular immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of PSA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased pain tolerance after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on neuropsychiatric symptom cluster
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment of agitation/aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial partial pressure of oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen saturation of hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genital symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colposcopy scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MV improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Favorable Glasgow Outcome Scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of significant bacteriuria after UDS
Endpoint domain: Adverse events/effects
Primary endpoint: dietetic knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Dynamic joint congruency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Tuftsin and IgM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Responder rate differences between treatment groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived quality of support
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reduction of viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Use of additional analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients reaching target BP (<140/<90 mm Hg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Cl (Chloride levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PAM (Pulmonary Artery Mean pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PC (Pulmonary Capillary wedge pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean P4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: No endometrial hyperplasia
Endpoint domain: Adverse events/effects
Primary endpoint: Improvements in menopausal vasomotor symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: satisfaction with training
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: dropout attrition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: training attrition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of SP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total scores of cases that passed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vasopressin-induced contractility of cervical strips
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: passive biomechanical properties (tensile strength, extensibility, stiffness of failure energy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in halitosis measured by Halimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of duodenal contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Amplitude of jejunal contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma motilin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement of cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Session-to-session changes in symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour fentanyl consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Herpes simplex virus lesions at delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Herpes simplex virus detection near delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Cesarean delivery for herpes simplex virus
Endpoint domain: Adverse events/effects
Primary endpoint: strength loss reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of malondialdehyde, creatine phosphokinase, myoglobin, leukocytes, and neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: migraine-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Neurocognitive performance on sustained attention task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of asking questions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Variety of medication-related questions asked
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Attendance at postpartum visit by 3 months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mood/behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Death, myocardial infarction, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Iron absorption from fortified bread
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: visual acuity < 6/18 in either eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean composite score of the visual function questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in UPDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ambulation speed improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of steps improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative time of erection-related moderate and severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: housing stability
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: community functioning
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: complete block rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative analgesic usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of force development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average VFCL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coefficient of variation of VFCL (cvVFCL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Platelet activation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory markers (IL-6, TNF-alpha, CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Early onset neonatal sepsis risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Term delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive functioning improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HD-PNI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in marijuana use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical therapeutic efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac measures of SC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urine catecholamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum fentanyl dose required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: teamwork behaviour
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: biopsy-confirmed first acute rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Steroid-free patients at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of dementia of the Alzheimer type (DAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of mild cognitive impairment (MCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinically significant gastrointestinal events (CSGIE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of iron deficiency anemia (IDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: supination strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalisation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global efficacy following the test meal
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: need for antacid rescue
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: peak heartburn severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of primary microvascular composite outcome of kidney and eye disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Success rate of sealant in the distopalatal groove using SeB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of sealant in the mesial groove using SeB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous lesions improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: pruritus improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in acromioclavicular stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior and superior displacement on radiographs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical measures of acromioclavicular stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite score of sexual function (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Serum concentration of luteinizing hormone (LH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum concentration of testosterone (T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PONH (Postoperative Nocturnal Hypoxemia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SatO2 < 85
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall incidence of composite adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean sedative dose of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percent reduction in total partial-seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Responder rates (≥50% reduction in total partial-seizure frequency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fatal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: specific IgE in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EELV-level increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Vt increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: LBI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: QTcDisp interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: affective symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity of vascular opacification scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Interobserver agreement in diagnosis of BD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to pharmacological guidelines for cardiovascular disease prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: isokinetic torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-m skating performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in amblyopic eye BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Formation and maximum strength of the fibrin clot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of CD28(‐) T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time of recovery of spontaneous ventilation, extubation and eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subcutaneous Fat Area (SFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visceral/Subcutaneous (V/S) Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lateral patellar tilt outliers (> 10°)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early stroke rate
Endpoint domain: Mortality/survival
Primary endpoint: Quality of life after early stroke
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Effectiveness of BSB dressings in treating diabetic foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in bronchial hyperresponsiveness (BHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: male overall distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: male global sexual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: female global sexual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean daily headache hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of analgesics per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of SUR reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of HIV infection
Endpoint domain: Adverse events/effects
Primary endpoint: Detectable drug concentrations at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SV volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nondiagnostic evaluation rates
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical fracture healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grey value changes of fracture sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of glomerular VEGF expression at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mortality at day-90
Endpoint domain: Mortality/survival
Primary endpoint: Quality of Life Index scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Short Form‐36 physical summary scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Partner concerns related to death and dysrhythmia recurrence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of drug-related adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Nasal symptom alleviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal blockade reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular symptom score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Access site pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New infarctions on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lesion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vasoconstriction (positive blanching effect)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Loss of dopamine transporter binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy and nutrient intake assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of subjects screened positive for eating disorders (ED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight and BMI among subjects with binge eating disorder (BED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of hospital admissions related to T2DM or any other condition
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean fasting LDL cholesterol levels after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skill level in interpretation of chest radiographs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant improvement in Constant score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of liquid removed from bottles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes